Previous Close | 0.5000 |
Open | 0.6500 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.5000 - 0.5000 |
52 Week Range | 0.4500 - 0.9200 |
Volume | |
Avg. Volume | 236 |
Market Cap | 5.516M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2500 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Beverly Hills, California., May 15, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire a 95% stake from eleven of Orocidin’s shareholders for $38,000,000. Nordicus will be issuing 38 million
Beverly Hills, California., May 09, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, today announced that it has uplisted to the OTCQB. OTCQB is recognized by the SEC as an established public securities market. OTCQB companies must provide current company financial information/news a
Beverly Hills, California., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTC PINK: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a paying Consultancy Agreement with Orocidin A/S in Denmark. Orocidin A/S (“Orocidin”) is a clinical-stage biopharmaceutical company focused on the discovery, deve